Pegaspargase
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Pegaspargase |
| DrugBank ID | DB00059 |
| Brand Names (EU) | Oncaspar |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | acute lymphoblastic leukemia (disease) | 99.99% | DL |
| 2 | leukemia, lymphocytic, susceptibility to | 99.98% | DL |
| 3 | acute lymphoblastic/lymphocytic leukemia | 99.97% | DL |
| 4 | precursor lymphoblastic lymphoma/leukemia | 99.96% | DL |
| 5 | chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation | 99.95% | DL |
| 6 | pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.95% | DL |
| 7 | follicular lymphoma | 99.90% | DL |
| 8 | acute lymphoblastic leukemia | 99.89% | DL |
| 9 | precursor T-cell acute lymphoblastic leukemia | 99.76% | DL |
| 10 | methylcobalamin deficiency type cblE | 99.74% | DL |
| 11 | lymphoid neoplasm | 99.71% | DL |
| 12 | Hodgkins lymphoma | 99.71% | DL |
| 13 | chronic lymphocytic leukemia/small lymphocytic lymphoma | 99.68% | DL |
| 14 | blast phase chronic myelogenous leukemia, BCR-ABL1 positive | 99.61% | DL |
| 15 | myeloid leukemia | 99.60% | DL |
| 16 | bladder transitional cell carcinoma | 99.41% | DL |
| 17 | Quinquaud’s folliculitis decalvans | 98.80% | DL |
| 18 | alopecia mucinosa | 98.76% | DL |
| 19 | telogen effluvium | 98.69% | DL |
| 20 | hereditary hypotrichosis with recurrent skin vesicles | 98.68% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.